Bio-imaging Market by Product (Imaging Systems, Instruments, Reagents), Technology (Endoscopy, Magnetic Resonance Imaging, Nuclear Imaging), Modality, Application, End User - Global Forecast 2025-2032
Description
The Bio-imaging Market was valued at USD 6.70 billion in 2024 and is projected to grow to USD 7.38 billion in 2025, with a CAGR of 10.50%, reaching USD 14.90 billion by 2032.
An incisive orientation to the contemporary bio-imaging landscape that frames technological convergence, clinical demand shifts, and strategic partnership imperatives
Bio-imaging sits at the intersection of technological innovation and clinical transformation, reshaping diagnostics, therapeutics, and research workflows. Advances in imaging modalities, coupled with software-driven analytics and reagent enhancements, have elevated the resolution, throughput, and interpretability of biological and clinical images. These improvements enable earlier disease detection, more precise surgical guidance, and accelerated pharmaceutical discovery, thereby aligning imaging capabilities with broader healthcare objectives such as value-based care and personalized medicine.
Moreover, the ecosystem surrounding bio-imaging has become more interconnected. Instrument manufacturers increasingly partner with software developers and reagent suppliers to deliver integrated solutions that reduce time-to-result and simplify end-user adoption. Concurrently, academic and industrial researchers are driving modality-specific innovations, while clinical settings are adapting protocols to capitalize on enhanced imaging fidelity. Taken together, these dynamics create both opportunities for disruption and practical imperatives for stakeholders to reassess product portfolios, go-to-market approaches, and cross-sector collaborations.
Exploring the fundamental disruptive trends that are accelerating modality innovation, digital integration, and procedural adoption across clinical and research settings
The bio-imaging landscape is undergoing transformative shifts driven by several convergent forces that are redefining value chains and competitive positioning. First, modality advances such as higher-field magnetic resonance, enhanced nuclear imaging tracers, and next-generation endoscopic visualization are extending clinical capabilities and expanding diagnostic indications. These modality-level improvements often translate into new clinical workflows and training requirements, prompting health systems to recalibrate adoption priorities.
Second, digital transformation is accelerating the integration of image analysis and data management software into routine practice. Artificial intelligence and machine learning are enabling automated image interpretation and quantification, thereby reducing variability and improving throughput. Third, the proliferation of minimally invasive surgical techniques has increased demand for compact, high-definition imaging and surgical microscopy technologies that support real-time decision-making. Finally, upstream factors such as reagent innovation and instrument miniaturization are making certain applications more accessible outside traditional hospital settings. Together, these shifts create a landscape in which agility, interoperability, and validated clinical utility become decisive differentiators.
Assessing how recent tariff policies and trade frictions are prompting supply-chain redesign, procurement reshaping, and cost management reactions across the bio-imaging value chain
The imposition of tariffs and trade policy changes in major economies can ripple across the bio-imaging value chain, affecting component sourcing, pricing strategies, and supply-chain resilience. Increased duties on imported imaging hardware components or reagents drive manufacturers to reassess supplier relationships and consider nearshoring or dual sourcing to protect production continuity. These shifts often lead to short-term cost increases and longer-term restructuring of procurement practices.
Consequently, organizations are responding by redesigning contracts, increasing inventory buffers for critical components, and accelerating localization of certain manufacturing steps. Regulatory packaging and labeling adaptations may also be required when supply bases change. From a commercial perspective, sales teams must adapt contract terms and pricing models to reflect altered landed costs and to preserve access for customers operating on constrained capital budgets. In parallel, research collaborations that depend on cross-border reagent shipments are implementing contingency plans to mitigate delays and maintain experimental timelines. Altogether, tariffs serve as a catalyst for supply-chain reconfiguration and risk mitigation strategies across the sector.
Comprehensive segmentation perspective that maps technology, product categories, modality differences, application demand, and end-user purchasing behaviors to strategic priorities
A nuanced understanding of segmentation yields actionable insight into where clinical demand, technology maturation, and purchasing dynamics intersect. Based on Technology, market participants must differentiate offerings across Endoscopy, Magnetic Resonance Imaging, Nuclear Imaging, Surgical Microscopy, Ultrasound, and X-ray Imaging, recognizing that each technology follows distinct innovation cycles, regulatory pathways, and clinical adoption curves. Product-level distinctions are equally important; based on Product, the landscape must account for imaging systems, instruments, reagents, and software. Instruments further break down into CT scanners, MRI machines, and ultrasound devices, each with unique capital requirements and service needs, while the Software component encompasses data management software and image analysis software that are increasingly critical to realizing clinical value.
Modal complexity adds another axis: based on Modality, 2D imaging and 3D imaging serve different diagnostic and interventional use cases, influencing acquisition protocols and downstream analytics. Application-driven demand further segments opportunity; based on Application, stakeholders should align solutions to clinical diagnostics, drug discovery, research, and therapeutics, recognizing that regulatory expectations and proof-of-concept requirements vary across these areas. Finally, end-user dynamics shape purchasing cycles and total cost of ownership; based on End User, adoption patterns differ across ambulatory surgical centers, diagnostic imaging centers, and hospitals & clinics. Integrating these segmentation lenses enables firms to prioritize product development, craft targeted clinical validation strategies, and tailor commercial models to match the procurement realities of each buyer type.
Regional strategic implications that reconcile heterogeneous adoption rates, regulatory regimes, and manufacturing capabilities across the Americas, EMEA, and Asia-Pacific markets
Regional dynamics continue to exert a defining influence on commercialization strategies and R&D localization. Across the Americas, demand patterns reflect a mix of advanced clinical adoption in urban centers and cost sensitivity in community settings, prompting vendors to offer differentiated service and financing options. Supply-chain considerations in this region emphasize speed-to-market for cutting-edge modalities while balancing interoperability with legacy infrastructure in larger health systems. In Europe, Middle East & Africa, heterogeneity is substantial: some markets demonstrate rapid uptake of minimally invasive imaging driven by policy incentives, while others prioritize affordability and robust service networks. In this region, harmonized regulatory frameworks and cross-border procurement consortia can enable scaled deployments when parties align on clinical guidelines.
The Asia-Pacific region presents a blend of fast-growing clinical demand and aggressive local manufacturing capabilities. Healthcare system investments in this region often prioritize capacity expansion and technology transfer, creating opportunities for partnerships that include knowledge transfer and localized manufacturing. Across all regions, reimbursement environments, clinical training infrastructures, and regional research priorities shape the most viable go-to-market tactics. Recognizing these differences allows companies to segment launch strategies, calibrate value messages, and design scalable post-sales support models tailored to each macro region.
Competitive mapping and strategic behaviors of OEMs, specialized instrument makers, reagent suppliers, and software innovators shaping partnerships, validation, and commercialization
Competitive dynamics in bio-imaging are defined by diversified players spanning global original equipment manufacturers, specialized instrument makers, reagent producers, and innovative software vendors. Incumbent OEMs retain strength through integrated solutions, established service networks, and regulatory experience, while specialist firms compete by offering highly optimized devices or niche reagents that address specific clinical gaps. Software providers and image analysis entrants are accelerating differentiation by deploying validated algorithms and creating platforms that facilitate interoperability with legacy systems.
Start-up activity remains robust in areas such as AI-driven image interpretation and cloud-enabled data management, where the pathway to adoption hinges on clinical validation and workflow integration rather than raw algorithmic performance alone. Partnerships and vertical integrations are common as companies seek to bundle instruments, reagents, and software into clinically validated offerings. Procurement and service models that emphasize outcomes, uptime guarantees, and predictable lifecycle costs are increasingly influential in purchasing decisions. Overall, successful companies combine technical excellence with scalable support models and clear evidence of clinical or operational return on investment.
Practical strategic moves for market leaders to accelerate adoption, lower integration friction, and enhance supply-chain resilience while demonstrating clinical value
Industry leaders should pursue a set of actionable priorities to convert market dynamics into sustainable advantage. First, prioritize interoperability by designing instruments and software that integrate seamlessly with existing hospital IT and imaging ecosystems, thereby reducing friction in procurement and clinical adoption. Second, invest in robust clinical validation programs that demonstrate reproducible outcomes across representative patient populations and care settings; validated evidence mitigates adoption barriers and accelerates reimbursement conversations. Third, diversify supply chains by identifying alternate suppliers and nearshoring opportunities for critical components and reagents to reduce exposure to trade disruptions and tariff volatility.
Additionally, companies should explore outcome-based commercial models and flexible financing mechanisms to address capital-constrained buyers in ambulatory and diagnostic imaging centers. Collaborations with academic and clinical partners can accelerate the generation of peer-reviewed evidence and facilitate early adopters. Finally, allocate resources to post-sale support and training services that minimize downtime and maximize the value proposition over the product lifecycle. These strategic moves, taken together, will strengthen market resilience and create differentiated customer experiences that drive long-term adoption.
A rigorous mixed-methods research framework combining primary stakeholder interviews, secondary technical review, and expert validation to ensure reliable strategic insights
The research synthesis draws upon a mixed-methods approach that combines primary interviews, secondary literature review, and cross-functional expert validation to ensure depth and accuracy. Primary engagement includes structured conversations with clinical leaders, procurement managers, R&D scientists, and supply-chain executives to obtain perspective on technology performance, adoption constraints, and procurement drivers. Secondary synthesis incorporates peer-reviewed literature, regulatory filings, technical white papers, and corporate disclosures to triangulate trends and confirm technical claims.
Qualitative findings were validated through expert workshops that reconciled differing stakeholder incentives and surfaced pragmatic implications for commercialization and development. The methodology emphasizes transparency in data sources, logical traceability between evidence and conclusions, and sensitivity analyses to account for regional regulatory variances and supply-chain contingencies. The approach intentionally balances technical rigor with accessibility to support decision-makers who require both high-level strategic guidance and pathway-level operational recommendations.
Synthesis of strategic imperatives that underscores clinical validation, interoperability, and resilient operations as decisive factors for long-term leadership
In conclusion, the bio-imaging domain is characterized by rapid technological advancement, shifting commercial models, and evolving regional dynamics that together create both complexity and opportunity. Stakeholders who align product development with clinical utility, prioritize interoperability, and implement resilient supply-chain strategies will be best positioned to capture value. The interplay between modality innovation, software-enabled analytics, and application-specific validation is central to unlocking sustained adoption across clinical diagnostics, therapeutics, and research environments.
Moving forward, success will depend on strategic partnerships that combine device excellence with validated analytics and dependable service delivery. Organizations that proactively adapt their commercial and operational models to regional nuances and emerging policy landscapes will accelerate adoption and minimize execution risk. Ultimately, a balanced emphasis on evidence generation, customer-centric support, and flexible operational design will determine which players lead in the evolving bio-imaging landscape.
Please Note: PDF & Excel + Online Access - 1 Year
An incisive orientation to the contemporary bio-imaging landscape that frames technological convergence, clinical demand shifts, and strategic partnership imperatives
Bio-imaging sits at the intersection of technological innovation and clinical transformation, reshaping diagnostics, therapeutics, and research workflows. Advances in imaging modalities, coupled with software-driven analytics and reagent enhancements, have elevated the resolution, throughput, and interpretability of biological and clinical images. These improvements enable earlier disease detection, more precise surgical guidance, and accelerated pharmaceutical discovery, thereby aligning imaging capabilities with broader healthcare objectives such as value-based care and personalized medicine.
Moreover, the ecosystem surrounding bio-imaging has become more interconnected. Instrument manufacturers increasingly partner with software developers and reagent suppliers to deliver integrated solutions that reduce time-to-result and simplify end-user adoption. Concurrently, academic and industrial researchers are driving modality-specific innovations, while clinical settings are adapting protocols to capitalize on enhanced imaging fidelity. Taken together, these dynamics create both opportunities for disruption and practical imperatives for stakeholders to reassess product portfolios, go-to-market approaches, and cross-sector collaborations.
Exploring the fundamental disruptive trends that are accelerating modality innovation, digital integration, and procedural adoption across clinical and research settings
The bio-imaging landscape is undergoing transformative shifts driven by several convergent forces that are redefining value chains and competitive positioning. First, modality advances such as higher-field magnetic resonance, enhanced nuclear imaging tracers, and next-generation endoscopic visualization are extending clinical capabilities and expanding diagnostic indications. These modality-level improvements often translate into new clinical workflows and training requirements, prompting health systems to recalibrate adoption priorities.
Second, digital transformation is accelerating the integration of image analysis and data management software into routine practice. Artificial intelligence and machine learning are enabling automated image interpretation and quantification, thereby reducing variability and improving throughput. Third, the proliferation of minimally invasive surgical techniques has increased demand for compact, high-definition imaging and surgical microscopy technologies that support real-time decision-making. Finally, upstream factors such as reagent innovation and instrument miniaturization are making certain applications more accessible outside traditional hospital settings. Together, these shifts create a landscape in which agility, interoperability, and validated clinical utility become decisive differentiators.
Assessing how recent tariff policies and trade frictions are prompting supply-chain redesign, procurement reshaping, and cost management reactions across the bio-imaging value chain
The imposition of tariffs and trade policy changes in major economies can ripple across the bio-imaging value chain, affecting component sourcing, pricing strategies, and supply-chain resilience. Increased duties on imported imaging hardware components or reagents drive manufacturers to reassess supplier relationships and consider nearshoring or dual sourcing to protect production continuity. These shifts often lead to short-term cost increases and longer-term restructuring of procurement practices.
Consequently, organizations are responding by redesigning contracts, increasing inventory buffers for critical components, and accelerating localization of certain manufacturing steps. Regulatory packaging and labeling adaptations may also be required when supply bases change. From a commercial perspective, sales teams must adapt contract terms and pricing models to reflect altered landed costs and to preserve access for customers operating on constrained capital budgets. In parallel, research collaborations that depend on cross-border reagent shipments are implementing contingency plans to mitigate delays and maintain experimental timelines. Altogether, tariffs serve as a catalyst for supply-chain reconfiguration and risk mitigation strategies across the sector.
Comprehensive segmentation perspective that maps technology, product categories, modality differences, application demand, and end-user purchasing behaviors to strategic priorities
A nuanced understanding of segmentation yields actionable insight into where clinical demand, technology maturation, and purchasing dynamics intersect. Based on Technology, market participants must differentiate offerings across Endoscopy, Magnetic Resonance Imaging, Nuclear Imaging, Surgical Microscopy, Ultrasound, and X-ray Imaging, recognizing that each technology follows distinct innovation cycles, regulatory pathways, and clinical adoption curves. Product-level distinctions are equally important; based on Product, the landscape must account for imaging systems, instruments, reagents, and software. Instruments further break down into CT scanners, MRI machines, and ultrasound devices, each with unique capital requirements and service needs, while the Software component encompasses data management software and image analysis software that are increasingly critical to realizing clinical value.
Modal complexity adds another axis: based on Modality, 2D imaging and 3D imaging serve different diagnostic and interventional use cases, influencing acquisition protocols and downstream analytics. Application-driven demand further segments opportunity; based on Application, stakeholders should align solutions to clinical diagnostics, drug discovery, research, and therapeutics, recognizing that regulatory expectations and proof-of-concept requirements vary across these areas. Finally, end-user dynamics shape purchasing cycles and total cost of ownership; based on End User, adoption patterns differ across ambulatory surgical centers, diagnostic imaging centers, and hospitals & clinics. Integrating these segmentation lenses enables firms to prioritize product development, craft targeted clinical validation strategies, and tailor commercial models to match the procurement realities of each buyer type.
Regional strategic implications that reconcile heterogeneous adoption rates, regulatory regimes, and manufacturing capabilities across the Americas, EMEA, and Asia-Pacific markets
Regional dynamics continue to exert a defining influence on commercialization strategies and R&D localization. Across the Americas, demand patterns reflect a mix of advanced clinical adoption in urban centers and cost sensitivity in community settings, prompting vendors to offer differentiated service and financing options. Supply-chain considerations in this region emphasize speed-to-market for cutting-edge modalities while balancing interoperability with legacy infrastructure in larger health systems. In Europe, Middle East & Africa, heterogeneity is substantial: some markets demonstrate rapid uptake of minimally invasive imaging driven by policy incentives, while others prioritize affordability and robust service networks. In this region, harmonized regulatory frameworks and cross-border procurement consortia can enable scaled deployments when parties align on clinical guidelines.
The Asia-Pacific region presents a blend of fast-growing clinical demand and aggressive local manufacturing capabilities. Healthcare system investments in this region often prioritize capacity expansion and technology transfer, creating opportunities for partnerships that include knowledge transfer and localized manufacturing. Across all regions, reimbursement environments, clinical training infrastructures, and regional research priorities shape the most viable go-to-market tactics. Recognizing these differences allows companies to segment launch strategies, calibrate value messages, and design scalable post-sales support models tailored to each macro region.
Competitive mapping and strategic behaviors of OEMs, specialized instrument makers, reagent suppliers, and software innovators shaping partnerships, validation, and commercialization
Competitive dynamics in bio-imaging are defined by diversified players spanning global original equipment manufacturers, specialized instrument makers, reagent producers, and innovative software vendors. Incumbent OEMs retain strength through integrated solutions, established service networks, and regulatory experience, while specialist firms compete by offering highly optimized devices or niche reagents that address specific clinical gaps. Software providers and image analysis entrants are accelerating differentiation by deploying validated algorithms and creating platforms that facilitate interoperability with legacy systems.
Start-up activity remains robust in areas such as AI-driven image interpretation and cloud-enabled data management, where the pathway to adoption hinges on clinical validation and workflow integration rather than raw algorithmic performance alone. Partnerships and vertical integrations are common as companies seek to bundle instruments, reagents, and software into clinically validated offerings. Procurement and service models that emphasize outcomes, uptime guarantees, and predictable lifecycle costs are increasingly influential in purchasing decisions. Overall, successful companies combine technical excellence with scalable support models and clear evidence of clinical or operational return on investment.
Practical strategic moves for market leaders to accelerate adoption, lower integration friction, and enhance supply-chain resilience while demonstrating clinical value
Industry leaders should pursue a set of actionable priorities to convert market dynamics into sustainable advantage. First, prioritize interoperability by designing instruments and software that integrate seamlessly with existing hospital IT and imaging ecosystems, thereby reducing friction in procurement and clinical adoption. Second, invest in robust clinical validation programs that demonstrate reproducible outcomes across representative patient populations and care settings; validated evidence mitigates adoption barriers and accelerates reimbursement conversations. Third, diversify supply chains by identifying alternate suppliers and nearshoring opportunities for critical components and reagents to reduce exposure to trade disruptions and tariff volatility.
Additionally, companies should explore outcome-based commercial models and flexible financing mechanisms to address capital-constrained buyers in ambulatory and diagnostic imaging centers. Collaborations with academic and clinical partners can accelerate the generation of peer-reviewed evidence and facilitate early adopters. Finally, allocate resources to post-sale support and training services that minimize downtime and maximize the value proposition over the product lifecycle. These strategic moves, taken together, will strengthen market resilience and create differentiated customer experiences that drive long-term adoption.
A rigorous mixed-methods research framework combining primary stakeholder interviews, secondary technical review, and expert validation to ensure reliable strategic insights
The research synthesis draws upon a mixed-methods approach that combines primary interviews, secondary literature review, and cross-functional expert validation to ensure depth and accuracy. Primary engagement includes structured conversations with clinical leaders, procurement managers, R&D scientists, and supply-chain executives to obtain perspective on technology performance, adoption constraints, and procurement drivers. Secondary synthesis incorporates peer-reviewed literature, regulatory filings, technical white papers, and corporate disclosures to triangulate trends and confirm technical claims.
Qualitative findings were validated through expert workshops that reconciled differing stakeholder incentives and surfaced pragmatic implications for commercialization and development. The methodology emphasizes transparency in data sources, logical traceability between evidence and conclusions, and sensitivity analyses to account for regional regulatory variances and supply-chain contingencies. The approach intentionally balances technical rigor with accessibility to support decision-makers who require both high-level strategic guidance and pathway-level operational recommendations.
Synthesis of strategic imperatives that underscores clinical validation, interoperability, and resilient operations as decisive factors for long-term leadership
In conclusion, the bio-imaging domain is characterized by rapid technological advancement, shifting commercial models, and evolving regional dynamics that together create both complexity and opportunity. Stakeholders who align product development with clinical utility, prioritize interoperability, and implement resilient supply-chain strategies will be best positioned to capture value. The interplay between modality innovation, software-enabled analytics, and application-specific validation is central to unlocking sustained adoption across clinical diagnostics, therapeutics, and research environments.
Moving forward, success will depend on strategic partnerships that combine device excellence with validated analytics and dependable service delivery. Organizations that proactively adapt their commercial and operational models to regional nuances and emerging policy landscapes will accelerate adoption and minimize execution risk. Ultimately, a balanced emphasis on evidence generation, customer-centric support, and flexible operational design will determine which players lead in the evolving bio-imaging landscape.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence powered algorithms in high throughput bio imaging workflows
- 5.2. Rise of multimodal PET MRI imaging platforms enabling comprehensive molecular diagnostics
- 5.3. Advancement of super resolution microscopy techniques for real time live cell imaging applications
- 5.4. Emergence of cloud based bio imaging data management solutions for scalable research collaboration
- 5.5. Growth of label free optical imaging modalities enhancing rapid tissue characterization workflows
- 5.6. Development of theranostic contrast agents for simultaneous imaging and targeted drug delivery
- 5.7. Integration of microfluidic lab on a chip systems with high resolution fluorescence microscopy
- 5.8. Adoption of digital pathology and whole slide imaging for accelerated cancer diagnostics and analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Bio-imaging Market, by Product
- 8.1. Imaging Systems
- 8.2. Instruments
- 8.2.1. CT Scanners
- 8.2.2. MRI Machines
- 8.2.3. Ultrasound Devices
- 8.3. Reagents
- 8.4. Software
- 8.4.1. Data Management Software
- 8.4.2. Image Analysis Software
- 9. Bio-imaging Market, by Technology
- 9.1. Endoscopy
- 9.2. Magnetic Resonance Imaging
- 9.3. Nuclear Imaging
- 9.4. Surgical Microscopy
- 9.5. Ultrasound
- 9.6. X-ray Imaging
- 10. Bio-imaging Market, by Modality
- 10.1. 2D Imaging
- 10.2. 3D Imaging
- 11. Bio-imaging Market, by Application
- 11.1. Clinical Diagnostics
- 11.2. Drug Discovery
- 11.3. Research
- 11.4. Therapeutics
- 12. Bio-imaging Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Diagnostic Imaging Centers
- 12.3. Hospitals & Clinics
- 13. Bio-imaging Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Bio-imaging Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Bio-imaging Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. BaySpec, Inc.
- 16.3.2. Bracco S.p.A.
- 16.3.3. Bruker Corporation
- 16.3.4. Canon Medical Systems Corporation
- 16.3.5. Digirad Corporation
- 16.3.6. Esaote S.p.A
- 16.3.7. Fujifilm Holdings Corporation
- 16.3.8. GE HealthCare Technologies, Inc.
- 16.3.9. Hitachi Medical Corporation
- 16.3.10. HT BioImaging Ltd
- 16.3.11. iThera Medical GmbH
- 16.3.12. Kitware, Inc.
- 16.3.13. Koninklijke Philips N.V.
- 16.3.14. Lantheus Medical Imaging, Inc.
- 16.3.15. M Squared Lasers Ltd.
- 16.3.16. MARS Bioimaging Limited
- 16.3.17. Medtronic PLC
- 16.3.18. MobileODT Ltd by Liger Medical LLC
- 16.3.19. Perspectum Ltd.
- 16.3.20. Quibim, S.L.
- 16.3.21. RadNet, Inc.
- 16.3.22. Rivanna Medical, Inc.
- 16.3.23. Samsung Medison Co., Ltd.
- 16.3.24. Siemens Healthineers
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
